Gene, Genetics, Genotype and In-Vitro - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene

Genetics

Genotype

In-Vitro

Osimertinib Resistance and EGFR Mutations in NSCLC Treatment

Bioengineer

JANUARY 16, 2024

In patients with T790M mutant NSCLC receiving osimertinib, 63% experienced loss of T790M at progression, commonly linked to histological transdifferentiation, KRAS mutations, or gene fusions. The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. months vs. 15.2

Genome

Genome Genomics Protein In-Vitro

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

The Pharma Data

DECEMBER 9, 2020

The Chinese biopharmaceutical industry is growing in leaps and bounds, but there is still a huge unmet need when it comes to getting patients access to the breakthrough therapeutic modalities and platforms like RNAi, cell and gene therapy and others. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo

In-Vivo In-Vitro Antibody Development

Osimertinib Resistance and EGFR Mutations in NSCLC Treatment

Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies

Stay Connected